A modified prescription-event monitoring study to assess the introduction of Seretide Evohaler™ in England: An example of studying risk monitoring in pharmacovigilance

Drug Safety

Volumn 30, Issue 8, 2007, Pages 681-695

  Perrio, Michael J ^a   Wilton, Lynda V ^a,b   Shakir, Saad A W ^a,b  

^a DRUG SAFETY RESEARCH UNIT   (United Kingdom)

^b UNIVERSITY OF PORTSMOUTH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; FLUTICASONE PROPIONATE PLUS SALMETEROL; NORFLURANE; SERETIDE EVOHALER; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADULT; AIRWAY OBSTRUCTION; ANAMNESIS; ANGINA PECTORIS; ARTHRALGIA; ARTICLE; ASTHMA; BLEPHARITIS; BRONCHOSPASM; BURNING SENSATION; CHILD; CHRONIC OBSTRUCTIVE LUNG DISEASE; COHORT ANALYSIS; COUGHING; DEMOGRAPHY; DIARRHEA; DIPLOPIA; DISEASE SEVERITY; DIZZINESS; DRUG ERUPTION; DRUG FATALITY; DRUG INDICATION; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; FAINTNESS; FEMALE; FOLLOW UP; GENERAL PRACTICE; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HEART LEFT VENTRICLE FAILURE; HEART PALPITATION; HEARTBURN; HOARSENESS; HOSPITAL ADMISSION; HUMAN; INCIDENCE; LOWER RESPIRATORY TRACT INFECTION; MAJOR CLINICAL STUDY; MALE; METERED DOSE INHALER; MOUTH PAIN; MUSCLE CRAMP; OCULAR PRURITUS; PALATE DISEASE; PARESTHESIA; PATIENT COMPLIANCE; PATIENT IDENTIFICATION; PREGNANCY; PRESCRIPTION; PRIORITY JOURNAL; PRURITUS; QUESTIONNAIRE; RISK ASSESSMENT; RISK FACTOR; RISK MANAGEMENT; ROSACEA; SKIN ATROPHY; SMOKING; SORE THROAT; TACHYCARDIA; THORAX PAIN; THRUSH; TREATMENT OUTCOME; UNITED KINGDOM; UPPER RESPIRATORY TRACT INFECTION; VISUAL DISORDER; VOMITING; WHEEZING;

ADULT; AEROSOL PROPELLANTS; AGED; ALBUTEROL; ANDROSTADIENES; ASTHMA; BRONCHODILATOR AGENTS; ENGLAND; FEMALE; HUMANS; HYDROCARBONS, FLUORINATED; MALE; METERED DOSE INHALERS; MIDDLE AGED; PREGNANCY; PRODUCT SURVEILLANCE, POSTMARKETING; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 34548060344     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-200730080-00005     Document Type: Article

References (42)

1. The Montreal protocol on substances that deplete the ozone layer. 2000 [online]. Available from URL: http://www.une-p.org/ozone/Montreal-Protocol/ Montreal-Protocol2000.shtml [Accessed 2006 Aug 23]
2. Ibiapina CC, Cruz AA, Camargos PA. Hydrofluoroalkane as a propellant for pressurized metered-dose inhalers: history, pulmonary deposition, pharmacokinetics, efficacy and safety [in Portuguese]. J Pediatr (Rio J) 2004; 80 (6): 441-6
3. Leach CL. The CFC to HFA transition and its impact on pulmonary drug development. Respir Care 2005; 50 (9): 1201-8
4. Gates BJ, Neumiller JJ. CFC Phaseout and Adances in Oral Inhalers. Advances in Pharmacy 2005; 3 (2): 131-142, 155
5. Zeidler M, Corren J. Hydrofluoroalkane formulations of inhaled corticosteroids for the treatment of asthma. Treat Respir Med 2004; 3 (1): 35-44
6. European Commission. European Community strategy for the phaseout of CFCs in metered dose inhalers, 1998 [online]. Available from URL: http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=CELEX:51998DC0603:EN:HTML [Accessed 2006 Aug 23]
7. European Agency for the Evaluation of Medicinal Products. Guideline for PMS studies for metered dose inhalers with new propellants. CPMP/180/95. 1995 [online]. Available from URL: http://www.emea.eu.int/pdfs/human/qwp/018095en.pdf [Accessed 2006 Sep 1]
8. International Conference on Harmonisation of Technical Requirements for Registration of Medicinal Products for Human Use. Pharmacovigilance planning E2E. 2004 [online]. Available from URL: http://www.ich.org [Accessed 2006 Aug 23]
9. Shakir SAW. Prescription-event monitoring. In: Strom BL, editor. Pharmacoepidemiology. 4th ed. Chichester, UK: John Wiley & Sons Ltd, 2005: 203-16
10. Allen & Hanburys. Seretide Accuhaler, summary of product characteristics. 2005
11. Allen & Hanburys. Flixotide Evohaler, summary of product characteristics. 2000
12. Allen & Hanburys. Serevent Evohaler, summary of product characteristics. 2006
13. Allen & Hanburys. Seretide Evohaler, summary of product characteristics. 2000
14. Reynolds NA, Lyseng-Williamson KA, Wiseman LR. Inhaled salmeterol/fluticasone propionate: a review of its use in asthma. Drugs 2005; 65 (12): 1715-34
15. Macdessi JS, Randell TL, Donaghue KC, et al. Adrenal crises in children treated with high-dose inhaled corticosteroids for asthma. Med J Aust 2003; 178 (5): 214-6
16. Todd GR, Acerini CL, Ross-Russell R, et al. Survey of adrenal crisis associated with inhaled corticosteroids in the United Kingdom. Arch Dis Child 2002; 87 (6): 457-61
17. Nelson HS, Weiss ST, Bleecker ER, et al. The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest 2006; 129 (1): 15-26
18. Allen & Hanburys. Seretide Evohaler, summary of product characteristics. 2005
19. Bateman ED, Silins V, Bogolubov M. Clinical equivalence of salmeterol/fluticasone propionate in combination (50/100 microg twice daily) when administered via a chlorofluorocarbon-free metered dose inhaler or dry powder inhaler to patients with mild-to-moderate asthma. Respir Med 2001; 95 (2): 136-46
20. van Noord JA, Lill T, Carillo Diaz T, et al. Clinical equivalence of a salmeterol/fluticasone proprionate combination product (50/500ug) delivered via a chlorofluorocarbon-free metered- dose inhaler with the Diskus™ in patients with moderate to severe asthma. Clin Drug Invest 2001; 21 (4): 243-56
21. Shakir SAW. Causality and correlation in pharmacovigilance. In: Talbot J, Waller P, editors. Stephens' detection of new adverse drug reactions. 5th ed. Chichester: John Wiley & Sons Ltd, 2003: 329-43
22. CIOMS/WHO. International ethical guidelines for biomedical research involving human subjects. Geneva: CIOMS/WHO, 2002
23. Royal College of Physicians of London. Guidelines on the practice of ethical research involving human subjects. London: Royal College of Physicians of London, 1996
24. General Medical Council. Confidentiality: protecting and providing information. Frequently asked questions Q7. London: General Medical Council, 2004: 9
25. Heeley E, Riley J, Layton D, et al. Prescription-event monitoring and reporting of adverse drug reactions. Lancet 2001; 358: 1872-3
26. Martin RM, Kapoor KV, Wilton LV, et al. Underreporting of suspected adverse drug reactions to newly marketed ("black triangle") drugs in general practice: observational study. BMJ 1998; 317 (7151): 119-20
27. Templeton L, Deehan A, Taylor C, et al. Surveying general practitioners: does a low response rate matter? Br J General Pract 1997; 47: 91-4
28. Fleming DM, Cross KW, Sunderland R, et al. Comparison of the seasonal patterns of asthma identified in general practitioner episodes, hospital admissions, and deaths. Thorax 2000; 55: 662-5
29. Wong JY, Zacharin MR, Hocking N, et al. Growth and adrenal suppression in asthmatic children on moderate to high doses of fluticasone propionate. J Paediatr Child Health 2002; 38 (1): 59-62
30. Sim D, Griffiths A, Armstrong D, et al. Adrenal suppression from high-dose inhaled fluticasone propionate in children with asthma. Eur Respir J 2003; 21 (4): 633-6
31. Visser MJ, van der Veer E, ma DS, et al. Side-effects of fluticasone in asthmatic children: no effects after dose reduction. Eur Respir J 2004; 24 (3): 420-5
32. CSM/MCA. Current problems in pharmacovigilance. 2001; 27: 10
33. Atkins PJ. Dry powder inhalers an overview. Respir Care 2005; 50 (10): 1304-12
34. Nathan RA, Rooklin A, Schoaf L, et al. Efficacy and tolerability of fluticasone propionate/salmeterol administered twice daily via hydrofluoroalkane 134a metered-dose inhaler in adolescent and adult patients with persistent asthma: a randomized, double-blind, placebo-controlled, 12-week study. Clin Ther 2006; 28 (1): 73-85
35. Nelson HS, Wolfe JD, Gross G, et al. Efficacy and safety of fluticasone propionate 44 microg/salmeterol 21 microg administered in a hydrofluoroalkane metered-dose inhaler as an initial asthma maintenance treatment. Ann Allergy Asthma Immunol 2003; 91 (3): 263-9
36. Pearlman DS, Peden D, Condemi JJ, et al. Efficacy and safety of fluticasone propionate/salmeterol HFA 134A MDI in patients with mild-to-moderate persistent asthma. J Asthma 2004; 41 (8): 797-806
37. You-Ning L, Humphries M, Du X, et al. Efficacy and safety of salmeterol/fluticasone propionate delivered via a hydrofluoroalkane metered dose inhaler in Chinese patients with moderate asthma poorly controlled with inhaled corticosteroids. Int J Clin Pract 2005; 59 (7): 754-9
38. Wilton LV, Pearce G, Mann RD. The use of newly marketed drugs in children and adolescents prescribed in general practice. Pharmacoepidemiol Drug Saf 1999; 8 Suppl. 1: S37-45
39. Maconochie N, Doyle P, Prior S. The National Women's Health Study: assembly and description of a population-based reproductive cohort. BMC Public Health 2004; 4: 35
40. Bahri P, Tsintis P. Pharmacovigilance-related topics at the level of the International Conference on Harmonisation (ICH). Pharmacoepidemiol Drug Saf 2005; 14 (6): 377-87
41. Tsintis P, La ME. CIOMS and ICH initiatives in pharmacovigilance and risk management: overview and implications. Drug Saf 2004; 27 (8): 509-17
42. Waller PC, Evans SJ. A model for the future conduct of pharmacovigilance. Pharmacoepidemiol Drug Saf 2003; 12 (1): 17-29